Navigation Links
Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
Date:9/7/2012

CRANBURY, N.J., Sept. 7, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner,  AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity.  AstraZeneca remains committed to this collaboration program and to the continued advancement of melanocortin agonists for treatment of obesity.

AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist, was a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies. As previously announced, a Phase I trial of AZD2820 was halted following a serious adverse event. The decision to discontinue development of the compound was made based on investigations and review conducted by AstraZeneca that followed this incident. While not confirmed, it could not be excluded that the serious adverse event was linked to AZD2820. The investigation further concluded that it is unlikely that the serious adverse event was related to melanocortin receptor activation as an approach for the treatment of obesity.

"We are pleased that the subject has fully recovered from this adverse event," said Dr. Carl Spana, President and Chief Executive Officer of Palatin. "The AZD2820 compound is part of a broader research and development collaboration with AstraZeneca. We have multiple classes of collaboration compounds in various stages of preclinical testing and AstraZeneca has informed us that they remain committed to the advancement of collaboration compounds for treatment of obesity."

Pursuant to the terms of the research collaboration and license agreement with AstraZeneca, Palatin is eligible for milestone payments upon achieving development and regulatory milestones and further payments on achievement of sales targets, in addition to royalties on sales of app
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
2. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
3. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
4. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
7. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
10. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
11. Life Technologies to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 According to a new ... - Global Industry Analysis, Size, Share, Growth, Trends and ... USD 25.16 billion in 2013, which is expected to ... CAGR of 10.4% from 2014 to 2020. ... Increasing demand for accurate early diagnosis and ...
(Date:8/1/2014)... Once a decision has been made to increase ... how to define your tolerance for lowest cost design ... Director of Facilities Integration at Fluor Industrial Services, Craig ... and special guest Carrier Li, Director in Global Asset ... provide an examination of the Conceptual Design process and ...
(Date:8/1/2014)... 2014 Cambrex Corporation (NYSE: CBM ) ... Highlights , Second quarter sales ... same period last year. , Second quarter EBITDA increased ... same period last year (see table at the end of ... excluding the impact of foreign currency, to between 13% and ...
(Date:8/1/2014)... Testing the mechanical properties of ... understanding embryonic development. How and why embryonic ... functionally distinct tissues is important because abnormalities can ... McDevitt, Melissa Kinney, and Rabbia Saeed worked from ... cues to control many aspects of embryo development. ...
Breaking Biology Technology:Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Study Links Biomechanics and Gene Expression in Stem Cells 2
... part of the,"SCIENCEsuisse" project, swissinfo.ch is presenting profiles ... disciplines. The focus is on,Switzerland,s high international reputation ... SSR idee suisse initiative, in collaboration with,the Swiss ... give readers an insight into what,scientists are studying ...
... Nov. 11 Accumetrics, Inc. has announced the,appointment of ... the company.,Dr. Young will serve in a part-time capacity ... and Director of the Cardiovascular,Innovations Program at The Ohio ... the main liaison to practicing clinicians, as well as,coordinating ...
... Potentia Pharmaceuticals, a,privately held biotechnology company developing ... announced today the appointments,of Johanna M. Seddon, M.D. ... Board effective November 6, 2008., Dr. Seddon ... pioneer,in nutritional and genetic research in age-related macular ...
Cached Biology Technology:25 Short Films About Top-Level Research on swissinfo.ch 2Accumetrics Appoints John J. Young, MD Chief Medical Officer 2Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board 2Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board 3
(Date:8/1/2014)... enormous opportunities for both biological and future clinical ... cells in the body, offering immense hope of ... kidney, liver and lung diseases and making damaged ... Prof. Jinhui Chen from Indiana University in USA ... myriad biological, ethical, legal, political, and financial challenges. ...
(Date:8/1/2014)... of phloem, the conductive tissue through which plants transport ... cylindrical cells are capped at one end by a ... which in turn form a network throughout a plant,s ... cells which play an important role in carbon sequestration, ... their differentiation," says Professor Yk Helariutta from the Institute ...
(Date:8/1/2014)... August 1, 2014 The Journal of Nutrition Education ... Best Great Educational Material (GEM) awards, which were presented ... annual conference, "Nutrition Education Impact: Local to Global," in ... These annual awards recognize the authors of the best ... as judged by members of the JNEB Journal Committee ...
Breaking Biology News(10 mins):Developmental regulation of important plant phloem components discovered 2
... first time, scientists at King,s College London have identified a ... brain to intelligence. The study is published today in ... behind some forms of intellectual impairment. The researchers ... human brain. It is known as ,grey matter, and plays ...
... , , , , , ... , , AUDIO: ... significantly... , Click here for more information. , ... , , , , , ...
... century, plants and animals will need to adapt or shift ... an innovative global map of where species are likely to ... The findings appear in the science journal Nature . ... Center for Ecological Analysis and Synthesis (NCEAS) working group, 18 ...
Cached Biology News:Scientists identify gene linking brain structure to intelligence 2Manga comics may help promote fruit consumption among youth 2Manga comics may help promote fruit consumption among youth 3Maps show expected redistribution of global species due to climate change 2Maps show expected redistribution of global species due to climate change 3
Anti-Goat HRP-DAB Cell & Tissue Staining Kit...
Anti-Goat HRP-AEC Cell & Tissue Staining Kit...
... provides all the materials necessary for the isolation ... antigen studies analysis. Kit Components: ... 5122) One bottle containing 220 mL of buffered ... (5X) - (Catalog No. 5113) One bottle containing ...
... CultureWell cell culture systems provide ... cultured cells for staining and ... silicone gaskets preassembled with standard ... plates. The entire system is ...
Biology Products: